IDE-161

Small molecule

Earlyevidence

Evidence outlook

Early-stage evidence only

Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1/2 (1)
Other / comorbidity
NCT07174583 · IDEAYA Biosciences
2025-10-14 – 2029-07 · Small-cell Lung Cancer, Neuroendocrine Carcinomas, Solid Tumor Show to Express DLL3
What this study did
Phase 1 (1)
Ovarian Cancer

Competitive landscape

This drug's own stage for Ovarian Cancer: Phase 1. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
IDE-161: this drugPhase 1Small moleculePARGnot yet gradedNo reviewed efficacy summary in this indication
Avutometinib / Defactinib (Avmapki Fakzynja Co-Pack)ApprovedSmall moleculeMEK1/2 and RAF (CRAF, BRAF), FAKnot yet gradedNo reviewed efficacy summary in this indication
BAT1706 (Avzivi)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
BevacizumabApprovedMonoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor Inhibitornot yet gradedNo reviewed efficacy summary in this indication
Gemcitabine
ApprovedUS marketing discontinued
Small moleculeribonucleotide reductase / DNA polymerase (dCTP competition)not yet gradedNo reviewed efficacy summary in this indication
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Mirvetuximab Soravtansine (Elahere)ApprovedAntibody–drug conjugate—not yet gradedNo reviewed efficacy summary in this indication
NiraparibApprovedSmall moleculePARP1/2Reliable signal
NCT02655016: Progression Free Survival (Up to 34 months): Placebo 8.2 Months (95% CI 7.3 to 8.5) | Niraparib 13.8 Months (95% CI 11.5 to 14.9)
OlaparibApprovedSmall moleculePARPnot yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Reliable signalNo reviewed efficacy summary in this indication
Relacorilant (Lifyorli)ApprovedSmall moleculeGlucocorticoid receptorPartial signalNo reviewed efficacy summary in this indication
RucaparibApprovedSmall moleculePARP (poly ADP-ribose polymerase) enzymes, PARP1/2Reliable signalFeatured results are non-efficacy only in this race
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
DurvalumabPhase 3Monoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
GSK 5733584Phase 3——not yet gradedNo reviewed efficacy summary in this indication
INCB123667Phase 3Small moleculeCDK2not yet gradedNo reviewed efficacy summary in this indication
Izalontamab BrengitecanPhase 3Antibody–drug conjugateEGFR + HER3not yet gradedNo reviewed efficacy summary in this indication
Olvimulogene NanivacirepvecPhase 3Oncolytic virusNo discrete molecular targetnot yet gradedNo reviewed efficacy summary in this indication
Raludotatug DeruxtecanPhase 3Antibody–drug conjugateCDH6 (Cadherin-6)not yet gradedNo reviewed efficacy summary in this indication
Rinatabart Sesutecan (Rina-S)Phase 3Antibody–drug conjugateFolate receptor alpha (FRα)not yet gradedNo reviewed efficacy summary in this indication
Sacituzumab TirumotecanPhase 3Antibody–drug conjugateTROP2not yet gradedNo reviewed efficacy summary in this indication
Sofetabart MipitecanPhase 3Antibody–drug conjugateFolate receptor alpha (FRα)not yet gradedNo reviewed efficacy summary in this indication
Torvutatug SamrotecanPhase 3Antibody–drug conjugateFolate receptor alpha (FRα)not yet gradedNo reviewed efficacy summary in this indication
Trastuzumab BrengitecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
Trastuzumab RezetecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
BirinapantPhase 2—IAP (inhibitor of apoptosis) proteinsnot yet gradedNo reviewed efficacy summary in this indication
Ixotatug VedotinPhase 2Antibody–drug conjugateClaudin 6 (CLDN6)not yet gradedNo reviewed efficacy summary in this indication
StenoparibPhase 2Small moleculePARP1/2, Tankyrase 1/2not yet gradedNo reviewed efficacy summary in this indication
COM701Phase 1/2Monoclonal antibodyPVRIG (CD112R)not yet gradedNo reviewed efficacy summary in this indication
REGN5668Phase 1/2Multispecific antibodyMUC16 x CD28not yet gradedNo reviewed efficacy summary in this indication
RezatapoptPhase 1/2Small moleculep53 reactivatornot yet gradedNo reviewed efficacy summary in this indication
TUB-040Phase 1/2Antibody–drug conjugateNaPi2b (sodium-dependent phosphate transporter, SLC34A2)not yet gradedNo reviewed efficacy summary in this indication
UbamatamabPhase 1/2Monoclonal antibodyMUC16 x CD3not yet gradedNo reviewed efficacy summary in this indication
27T51Phase 1Cell therapyMUC16not yet gradedNo reviewed efficacy summary in this indication
ABBV-901Phase 1UndisclosedFolate receptor alpha (FRα)not yet gradedNo reviewed efficacy summary in this indication
APG-2449Phase 1Small moleculeFAK / ALK / ROS1not yet gradedNo reviewed efficacy summary in this indication
CRX100Phase 1Cell therapyCell-based oncolytic virus immunotherapynot yet gradedNo reviewed efficacy summary in this indication
XmAb541Phase 1Multispecific antibodyClaudin 6 (CLDN6) x CD3not yet gradedNo reviewed efficacy summary in this indication
Luveltamab TazevibulinDiscontinuedAntibody–drug conjugateFolate receptor alpha (FRα)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow IDE-161 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2029 (1)
July 2029 (1)
Phase 1/2Small-cell Lung Cancer, Neuroendocrine Carcinomas, Solid Tumor Show to Express DLL3Recruiting
Est. primary completion 2029-07 · NCT07174583 · CT.gov ↗
What to watch

See the full readout calendar ↗